过敏原免疫治疗对新致敏发生影响的荟萃分析
该系统综述纳入8项研究共721例儿童,比较尘螨过敏原免疫治疗(AIT)与药物治疗对新过敏原致敏发生的影响。荟萃分析显示AIT与药物治疗无差异(RD -0.10,95%CI -0.31至0.11,p=0.32),异质性高(I2=91.4%),证据等级低。结论不支持AIT预防新致敏发生。
要点
- AIT与药物治疗在新致敏发生风险上无差异(RD -0.10,95%CI -0.31至0.11,p=0.32)。
- 8项研究中仅3项报告AIT组新致敏发生减少,但整体证据等级低。
- 异质性高(I2=91.4%),研究间结果不一致。
核心结论
- 系统综述数据不支持尘螨AIT相比药物治疗能预防儿童新过敏原致敏的发生。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane Library至2016年11月30日。
- 纳入8项随机对照试验或观察性研究,共721例儿童(AIT组390例,药物治疗组331例),观察期至少3年(含治疗和随访)。
主要发现
- 8项研究中有3项报告AIT组相比药物治疗组新致敏发生减少。
- 荟萃分析显示AIT与药物治疗无差异(RD -0.10,95%CI -0.31至0.11,p=0.32),异质性高(I2=91.4%)。
- 偏倚风险高,低证据等级支持AIT预防新致敏的结论。
关键数值与推荐
- AIT组390例 vs 药物治疗组331例,新致敏风险差异RD -0.10(95%CI -0.31至0.11,p=0.32)。
- 异质性I2=91.4%。
临床怎么用
- 当前证据不支持将尘螨AIT用于预防儿童新过敏原致敏的发生。
局限性
- 偏倚风险高。
- 证据等级低。
- 异质性高(I2=91.4%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. METHODS: Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-analyses were performed. Randomized controlled trials or observational studies comparing children treated with AIT with house dust mite (HDM) to subjects who did not receive AIT, with a long-term observation period (at least 3 years including treatment and follow-up) have been included. RESULTS: Eight studies totaling 721 children (390 treated with AIT and 331 with pharmacotherapy) met the inclusion criteria. The risk of bias was high. Low evidence supports the conclusion that AIT prevents the onset of new allergen sensitizations, with 3 of 8 studies reporting a reduction in the onset of new sensitizations in patients treated with AIT vs pharmacotherapy. Our meta-analysis found no difference between AIT and pharmacotherapy, with high heterogeneity (RD, -0.10; 95% confidence interval [CI], -0.31 to 0.11; p = 0.32; I2 = 91.4%). CONCLUSION: The data of this systematic review do not support a preventive effect in the onset of new allergen sensitizations, in children treated with AIT in comparison with those treated with pharmacotherapy.
引用
- Di Lorenzo G, Leto-Barone MS, La Piana S, et al. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. Int Forum Allergy Rhinol. 2017. PMID: 28544523. doi:10.1002/alr.21946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。